DPP4 and neoplasm: Interestingly, preliminary data also indicate that treatment with the CD26/DPP4 inhibitor sitagliptin impaired the migration of CD26hi mesothelin-specific CAR T cells, thus limiting tumor infiltration by CD26hi T cells resulting in impaired tumor control.